EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
News|Articles|September 8, 2010
Read Between the Lines
When a patient complains of a “sore that won’t heal” or mentions that a lesion “constantly bleeds and scabs,” heed the advice of Osler.
Advertisement
When a patient complains of a "sore that won't heal" or mentions that a lesion "constantly bleeds and scabs," heed the advice of Osler: "Listen to the patient, he is telling you the diagnosis." This characteristic description best fits the diagnosis of a basal cell carcinoma.
--
Benjamin Barankin, MD
Toronto
Advertisement
Related to this article
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
ACOG Issues Expanded Guideline on Managing Menopause-Related Vasomotor, Sleep, and Mood Symptoms
2
Capsule-Sponge Testing Could Help Close the Barrett’s Screening Gap: An Expert Q&A
3
Actigraphy and Objective Sleep Outcomes in Menopause VMS Treatment
4
Mirikizumab Linked to Higher Rates of Corticosteroid-Free Composite Remission in UC and Crohn Disease
5